TABLE 1.
Comparison of disease states treated with lecanemab and four other commonly used biologic therapies
| Lecanemab | Trastuzumab | Bevacizumab | Etanercept | Ocrelizumab | |
|---|---|---|---|---|---|
| Indication | Dementia (Alzheimer's disease as the leading cause) | Breast cancer | Lung cancer | Rheumatoid arthritis (all organ involvement) | Multiple sclerosis |
| No. of persons with disease in the US 2023 | 6,700,000 | 3,886,830 | 603,989 | 1,300,000 | 744,781 |
| No. of deaths from the disease in the US 2018–2021 a | 619,539 | 216,237 | 603,253 | 474 | 28,716 |
| Prevalence of disease (per 100,000 population) | 1994.7 | 1157.2 | 179.8 | 387.0 | 221.7 |
| Deaths due to disease (per 100,000 population) in the US 2018–2021 a | 47.0 | 16.4 | 45.8 | 0.0 | 2.2 |
| Wholesale acquisition cost b | $26,500 | $79,479 | $82,882 | $96,224 | $78,858 |
| Efficacy (derived from FDA package label) | 27%–40% slowing of decline in cognitive and functional outcomes | Reduces mortality by 33% | 20% improvement in PFS | 31% remission; 45% low disease activity | 46% reduction in relapse rate; 24% slowing in primary progressive MS |
| NNT | 14–18 | 13–35 | 15 | 3–6 | 16 |
| Black box warning (derived from FDA package label) | Amyloid related imaging abnormalities | Cardiomyopathy, infusion reactions, and Pulmonary toxicity | Gastrointestinal perforations; surgery and wound healing complications; and hemorrhage | Serious infections and malignancies | No black box warning |
| Risk of death due to drug (calculated from FDA package label) | 0.1% | 0.8% | 2.5% | 0.1% | 0.3% |
| Risk of serious TEAEs (calculated from FDA package label) | 7% | 15% | 31% | 7% | 18.1% |
Abbreviations: FDA, United States Food and Drug Administration; NNT, number needed to treat; PFS, progression free survival; TEAE, treatment emergent adverse event.
a
Data derived from IPD Analytics 2024.
b
Data derived from Center for Disease Control and Prevention (CDC) WONDER representing provisional mortality rates.